Watch for Andexxa, the New Apixaban and Rivaroxaban Reversal Agent
July 2018
You'll hear about Andexxa (an-DEK-sah, inactivated recombinant factor Xa), the new, IV direct oral anticoagulant (DOAC) reversal agent.
Andexxa binds and inactivates factor Xa inhibitors...compared to idarucizumab (Praxbind), which reverses dabigatran (Pradaxa).
Andexxa's FDA approval is based on quick reversal of clotting time in patients taking apixaban and rivaroxaban. But it's also being studied with other anticoagulants...betrixaban (Bevyxxa), edoxaban (Savaysa), and enoxaparin.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote